Syneos Health announced the release of its survey “Real World Value: Advancing Payer Understanding of RWE in Rare Disease.” The survey talks about the perception gap that payers have surrounding RWE benefits for rare disease therapies. It also provides feedback from more than 300 payers in the U.S. and Europe, exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time.
Some of the survey findings include:
Read or download the full report here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.